Company Insights

MCK customer relationships

MCK customer relationship map

McKesson (MCK): Customer Relationships Drive Revenue — Concentration Is the Strategic Risk

McKesson distributes pharmaceuticals and delivers health‑care technology, supplies, and care‑management services, monetizing through distribution margins, long‑term supply contracts with large retail and institutional customers, and recurring technology and services fees. Revenue is structurally concentrated around a handful of counterparty relationships and purchasing channels, creating predictable cash flow but also single‑point risks that investors must price into the valuation. For a concise view of relationship risk and exposures, visit https://nullexposure.com/.

How McKesson actually makes money and how that shapes customer risk

McKesson’s core business is volume distribution across U.S. pharmaceuticals and medical‑surgical products, complemented by services and technology (Rx technology services, leasing, infusion, and specialty pharmacy support). The company realizes revenue through large, often contractual sales to retailers, health systems, group purchasing organizations (GPOs), and government purchasers, and through recurring service fees in its RxTS and Medical‑Surgical segments. These contract and channel dynamics produce high revenue concentration, durable counterparty dependencies, and operational criticality for both McKesson and its customers.

  • Concentration: McKesson reports its ten largest customers, including GPOs, accounted for approximately 72% of consolidated revenues in FY2025 — a material concentration that compresses counterparty diversification but supports scale economics.
  • Contracting posture: The company operates largely under long‑standing supply agreements and purchasing‑channel relationships, which embed volume and payment terms that are commercially favorable but expose McKesson to counterparty credit risk.
  • Criticality and maturity: Relationships with national pharmacy chains, health systems, and government purchasers are highly critical to revenue and reflect a mature, sticky business model across distribution and services.

What the filings show — relationship by relationship

Rite Aid Corporation

Rite Aid’s bankruptcy produced a notable credit loss for McKesson: the company recorded a $725 million provision for bad debts tied to Rite Aid for the years ended March 31, 2025 and 2024, reflecting the customer’s Chapter 11 filing in fiscal 2024. According to McKesson’s FY2025 Form 10‑K, the bankruptcy had a direct earnings and cash‑collection impact on trade receivables. (Source: McKesson FY2025 Form 10‑K).

CVS Health Corporation

CVS is McKesson’s largest customer by dollar volume: sales to CVS represented approximately 24% of consolidated revenues in fiscal 2025 and comprised roughly 23% of trade receivables at March 31, 2025. This single‑customer weight is an explicit material exposure that anchors both revenue and working capital dynamics. (Source: McKesson FY2025 Form 10‑K).

Government entities, agencies and GPOs

McKesson maintains agreements with group purchasing organizations (GPOs) and with government entities and agencies, where GPOs act as purchasing agents for hospitals, pharmacies and other healthcare providers. These channels are embedded across the U.S. Pharmaceutical and Medical‑Surgical segments and represent both stable demand and negotiated pricing/leverage points. (Source: McKesson FY2025 Form 10‑K).

What these relationships imply for investors

The filings and relationship excerpts give clear, actionable signals about McKesson’s risk‑return profile:

  • Revenue concentration is material and structural. With the ten largest customers representing ~72% of revenue, investor returns hinge on retention and credit performance of a small set of counterparties rather than broad retail fragmentation. That concentration compresses downside risk tolerance for unexpected bankruptcies or contract renegotiations.
  • Counterparty credit risk is real and executable. The Rite Aid charge demonstrates how customer insolvency translates directly to large provisioning and receivable write‑offs; the CVS share of revenue shows the symmetric exposure to any commercial or pricing pressure from major retail partners.
  • Government/GPO relationships create both stability and margin pressure. Contracts through GPOs and government channels provide scale but often involve tight pricing and centralized negotiation — a structural margin constraint even as volume remains high.
  • Business model maturity reduces execution risk but elevates oligopsony exposure. McKesson’s scale and service breadth (distribution, RxTS, medical‑surgical logistics, leasing) signal an established, low‑beta business — consistent with the company’s historical margins — but the customer base functions as a small set of powerful buyers.

For investors wanting deeper, relationship‑level analytics and covenant visibility, explore structured relationship reports at https://nullexposure.com/.

Segment and role signals that matter for valuation

Several company‑level signals from the FY2025 filing clarify where revenue and risk concentrate across McKesson’s operating model:

  • Primary role: Distributor and service provider. The U.S. Pharmaceutical segment and Medical‑Surgical Solutions are built on distribution logistics; RxTS supplies recurring technology services that monetize via SaaS‑like workflows, prior authorization, and dispensing support.
  • Geography: North America dominated. The U.S. pharmaceutical distribution footprint is the principal revenue engine, anchoring exposure to U.S. retail and institutional healthcare cycles.
  • Materiality: Both critical and material exposures documented. The filings classify the overall customer set as critical to revenue (top customers = 72% of revenue) and call out CVS specifically as material at ~24% of revenue; investors must treat both company‑level concentration and single‑counterparty exposure as active valuation inputs.

Investor action points

  • Stress‑test working capital and credit losses against scenarios where one or two large customers encounter distress; use the Rite Aid charge as a realized loss benchmark.
  • Monitor contract renewals with CVS and GPOs closely; any shift in procurement terms will materially affect revenue and margin.
  • Assess margin pressure from government/GPO channels as a structural constraint on gross margins even as volumes scale.

For a focused, investor‑grade breakdown of McKesson’s counterparty exposures and to download relationship summaries, visit https://nullexposure.com/.

Bottom line

McKesson’s scale and diversified service set underpin durable earnings, but the firm’s revenue profile is structurally concentrated around a few very large customers and purchasing channels. Credit events and contract renegotiations among those counterparties can produce immediate and material P&L and balance sheet impacts, as evidenced by the Rite Aid loss and the outsized share of revenue from CVS and GPO channels. Investors should price McKesson as a mature distributor with low operational execution risk but elevated counterparty concentration risk, and allocate monitoring resources accordingly.

Take the next step: review McKesson’s customer relationship map and scenario outputs at https://nullexposure.com/.